Get the Stockscreener App
120.16
0.30%
-0.36
Incyte Corp stock is traded at $120.16, with a volume of 785.74K.
It is down -0.30% in the last 24 hours and up +4.60% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$120.52
Open:
$119.15
24h Volume:
785.74K
Relative Volume:
0.43
Market Cap:
$24.36B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
16.99
EPS:
7.0718
Net Cash Flow:
$1.42B
1W Performance:
-0.33%
1M Performance:
+4.60%
6M Performance:
+18.85%
1Y Performance:
+39.46%
1-Day Range:
$117.56
$120.44
1-Week Range:
$117.56
$122.69
52-Week Range:
$81.09
$132.60
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
120.16 | 24.48B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte Corp's Pablo J. Cagnoni Sells 10,803 Shares Under Rule 10b5-1 Plan in August 2026 - Kalkine Media
Incyte Corp (INCY) R&D chief sells 10,803 shares under Rule 10b5-1 plan - Stock Titan
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? - Yahoo Finance
Incyte stock gains support as Q2 2026 sales surge and guidance rises - AD HOC NEWS
Incyte Sales Growth Drives Share Price Gains - FXEmpire
Insight Wealth Strategies LLC Acquires New Position in Incyte Corporation $INCY - MarketBeat
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
LTS:0J9P EV-to-OCF: 10.12 — 48% Below Median - GuruFocus
Incyte Corp (HAM:ICY) Stock Price, Trades & News - GuruFocus
Incyte Corporation (NASDAQ:INCY): What Could Drive Shares Next? - Kalkine Media
Incyte (INCY) Short Interest & Short Float | Updated Aug 2026 $INCY - MarketBeat
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bank of America Corp DE Sells 87,913 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Finviz
Incyte Corp. stock outperforms competitors on strong trading day - marketwatch.com
Incyte Corp (INCY) R&D head sells 10,640 shares in plan trade - Stock Titan
Incyte Corp (INCY) EVP sells 2,207 shares after option exercise - Stock Titan
Incyte Corp (ICY.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp. stock outperforms competitors despite losses on the day - marketwatch.com
Incyte (NASDAQ:INCY) EVP Sells $5,005,254.54 in Stock - MarketBeat
Incyte Corp (INCY) R&D head sells 15,888 shares, retains 215,444 - Stock Titan
Incyte Corp (INCY) EVP sells 47,954 shares after exercising options - Stock Titan
Quantinno Capital Management LP Raises Position in Incyte Corporation $INCY - MarketBeat
The Manufacturers Life Insurance Company Sells 30,324 Shares of Incyte Corporation $INCY - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on JAK inhibitor data - Investing.com
Amundi Purchases 229,783 Shares of Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In? - Yahoo Finance
Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors - marketwatch.com
Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance
Incyte Corporation $INCY Shares Acquired by Edgestream Partners L.P. - MarketBeat
Incyte Earnings: Opzelura Settlement and Latarcibart Improve Outlook Ahead of Jakafi Patent Loss - Morningstar
No-Moat Incyte Faces Jakafi Patent Cliff as Focus Remains on Opzelura and Expanding Portfolio - Morningstar
Incyte Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod - Stocktwits
Incyte lifts annual revenue forecast after settlement with CMS - pharma.economictimes.indiatimes.com
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript - AlphaStreet
Incyte stock jumps after Q2 beat and sharply higher 2026 sales outlook - Quiver Quantitative
A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options - Benzinga
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition - Benzinga
Incyte Q2 Earnings Call Highlights - Yahoo Finance
INCY Looks 18.3% Overvalued on GF Value™ as Growth Momentum Rema - GuruFocus
Earnings call transcript: Incyte Q2 2026 beats forecasts, lifts guidance - Investing.com
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte Q2 Results: Adj. EPS $3.09 Beats Estimate, Sales Rise 37% - scanx.trade
INCY Looks 18.4% Overvalued on GF Value™ as of July 28, 2026 - GuruFocus
Incyte (INCY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance Australia
INCY Looks 18.4% Overvalued on GF Value™ - GuruFocus
INCY Looks 18.4% Overvalued on GF Value™ as Growth Outlook Stren - GuruFocus
Is Incyte Corp (INCY) Worth the Current Valuation After Q2 Earni - GuruFocus
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):